slc25a34 Antibody

What is SLC25A34 and why is it important for mitochondrial research?

SLC25A34 is a member of the solute carrier family 25, a group of proteins involved in mitochondrial transport. In humans, the canonical protein consists of 304 amino acid residues with a molecular mass of approximately 32.2 kDa. Its subcellular localization is in the mitochondrial inner membrane, where it functions as a multi-pass membrane protein . As a member of the Mitochondrial carrier (TC 2.A.29) protein family, SLC25A34 plays a potential role in metabolite transport across the mitochondrial membrane. Understanding this protein is crucial for mitochondrial research because carrier proteins regulate the exchange of substrates, metabolites, and cofactors across the inner mitochondrial membrane, thereby influencing metabolic pathways and cellular energetics. Research into SLC25A34 may provide insights into mitochondrial functions and their role in various physiological and pathological conditions.

What types of SLC25A34 antibodies are available for research applications?

Multiple types of SLC25A34 antibodies are available for research applications, varying in their species reactivity, clonality, and applications. Most commonly available are rabbit polyclonal antibodies that recognize specific epitopes of human, mouse, and rat SLC25A34 . These antibodies are available in unconjugated forms and have been validated for various applications including Western Blot (WB), Enzyme-Linked Immunosorbent Assay (ELISA), Immunocytochemistry (ICC), and Immunofluorescence (IF) . Some antibodies are designed to target specific regions of the protein, such as the middle region, while others may recognize the full-length protein or specific epitopes. The selection of the appropriate antibody depends on the specific research question, experimental conditions, and the species being studied.

How conserved is SLC25A34 across species and how does this affect antibody selection?

SLC25A34 is relatively conserved across multiple species, with orthologs reported in mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken species . This conservation is reflected in the cross-reactivity of many commercially available antibodies. When selecting an antibody for your research, it's important to consider the specific sequence homology between species in the region targeted by the antibody. Some antibodies show broader cross-reactivity (human, mouse, rat, bovine, dog, guinea pig, hamster, pig, yeast, zebrafish) while others may be more limited in their species reactivity . The conservation of SLC25A34 suggests its fundamental importance in mitochondrial function across different organisms. For comparative studies across species, select antibodies validated for cross-reactivity with your species of interest, or alternatively, choose species-specific antibodies when focusing on unique aspects of the protein in a particular organism.

What are the most common applications for SLC25A34 antibodies in research?

The most common applications for SLC25A34 antibodies in research include Western Blot (WB) and ELISA, with some antibodies also validated for Immunocytochemistry (ICC) and Immunofluorescence (IF) . Western Blot is particularly useful for detecting and quantifying SLC25A34 protein expression levels in tissue or cell lysates, allowing researchers to compare expression across different experimental conditions. ELISA provides a sensitive method for quantitative detection of the protein in solution. ICC and IF applications enable visualization of the subcellular localization of SLC25A34, confirming its presence in the mitochondria and potentially revealing changes in localization under different physiological or pathological conditions. Each application requires specific optimization of antibody concentration, incubation conditions, and detection methods for optimal results.

What is the recommended protocol for using SLC25A34 antibodies in Western Blot?

For Western Blot applications using SLC25A34 antibodies, the following methodological approach is recommended:

• Sample preparation: Prepare cell or tissue lysates using an appropriate lysis buffer containing protease inhibitors to prevent protein degradation.

• Protein quantification: Determine protein concentration using a Bradford or BCA assay to ensure equal loading.

• SDS-PAGE: Separate proteins (typically 20-50 μg per lane) on an SDS-PAGE gel (10-12% is suitable for the 32.2 kDa SLC25A34 protein).

• Transfer: Transfer proteins to a PVDF or nitrocellulose membrane.

• Blocking: Block the membrane with 5% non-fat milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody incubation: Dilute the SLC25A34 antibody according to the manufacturer's recommendations (typically 1:500 to 1:2000) in blocking buffer and incubate overnight at 4°C.

• Washing: Wash the membrane 3-5 times with TBST.

• Secondary antibody incubation: Incubate with an appropriate HRP-conjugated secondary antibody (anti-rabbit for most SLC25A34 antibodies) for 1 hour at room temperature.

• Detection: Develop using ECL substrate and image using a digital imaging system.

• Analysis: Quantify band intensity using image analysis software for semi-quantitative comparison.

The expected band for human SLC25A34 should appear at approximately 32.2 kDa .

How should researchers optimize immunofluorescence experiments with SLC25A34 antibodies?

To optimize immunofluorescence experiments with SLC25A34 antibodies, researchers should follow this methodological approach:

• Cell preparation: Culture cells on appropriate coverslips or chamber slides. For mitochondrial proteins like SLC25A34, ensure cells are well-spread to visualize the mitochondrial network.

• Fixation: Fix cells with 4% paraformaldehyde for 15 minutes at room temperature. Alternatively, methanol fixation (100% methanol, -20°C, 10 minutes) may better preserve mitochondrial structures.

• Permeabilization: Permeabilize with 0.1-0.5% Triton X-100 in PBS for 10 minutes at room temperature if using paraformaldehyde fixation (not required for methanol fixation).

• Blocking: Block with 1-5% BSA or normal serum in PBS for 30-60 minutes at room temperature.

• Primary antibody: Dilute SLC25A34 antibody to the recommended concentration (typically 1-4 μg/ml for immunofluorescence applications) . Incubate overnight at 4°C or for 1-2 hours at room temperature.

• Co-staining: For mitochondrial localization confirmation, co-stain with established mitochondrial markers such as MitoTracker or antibodies against other mitochondrial proteins (e.g., TOMM20, COX IV).

• Washing: Wash 3 times with PBS.

• Secondary antibody: Incubate with fluorophore-conjugated secondary antibody for 1 hour at room temperature in the dark.

• Nuclear counterstain: Stain nuclei with DAPI or Hoechst.

• Mounting: Mount slides with anti-fade mounting medium.

Optimization should include testing different antibody concentrations, incubation times, and fixation methods to achieve the best signal-to-noise ratio while preserving the mitochondrial structure.

How can researchers validate the specificity of SLC25A34 antibodies in their experimental system?

Validating antibody specificity is crucial for reliable research results. For SLC25A34 antibodies, researchers should implement multiple validation strategies:

• Positive and negative control samples: Use tissues or cell lines with known high expression (e.g., based on RNA-seq data) and tissues/cells with low or no expression of SLC25A34.

• Knockdown or knockout validation: Perform siRNA knockdown or CRISPR/Cas9 knockout of SLC25A34 and demonstrate reduced or absent antibody signal.

• Overexpression studies: Express tagged SLC25A34 and confirm co-localization with the antibody signal.

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide before application to samples. A specific antibody will show reduced or eliminated signal.

• Multiple antibodies comparison: Use different antibodies targeting different epitopes of SLC25A34 and compare results.

• Mass spectrometry validation: Perform immunoprecipitation with the SLC25A34 antibody followed by mass spectrometry to confirm the identity of the precipitated protein.

• Cross-reactivity assessment: Test the antibody on samples from species where it is not expected to cross-react based on sequence differences.

Some SLC25A34 antibodies have undergone specificity verification through protein array testing against the target protein plus 383 other non-specific proteins , providing an additional level of validation.

What are the challenges in studying SLC25A34 expression in different tissues and how can they be overcome?

Studying SLC25A34 expression across tissues presents several challenges:

• Variable expression levels: SLC25A34 may have tissue-specific expression patterns, requiring sensitive detection methods for tissues with low expression.

• Mitochondrial protein extraction: Efficient extraction of mitochondrial membrane proteins requires specialized protocols.

• Antibody penetration in tissue sections: Mitochondrial membrane proteins may require enhanced antigen retrieval methods.

• Background signal: Non-specific binding can be particularly challenging in certain tissues.

• Cross-reactivity with related SLC25 family members: The SLC25 family has many members with structural similarities.

To overcome these challenges:

• Optimize protein extraction: Use specialized extraction buffers for mitochondrial membrane proteins, containing appropriate detergents (e.g., 1% Triton X-100, 0.5% SDS, or 1% CHAPS).

• Enhance antigen retrieval: For IHC applications, test multiple antigen retrieval methods (heat-induced epitope retrieval with citrate buffer pH 6.0 or EDTA buffer pH 9.0).

• Adjust blocking conditions: Increase blocking time or concentration (5-10% normal serum or BSA) to reduce background.

• Use mitochondrial enrichment: Perform mitochondrial isolation before Western blot analysis to enhance sensitivity.

• Employ multiple detection methods: Combine protein detection (Western blot/IHC) with mRNA analysis (RT-qPCR, in situ hybridization) for comprehensive expression profiling.

• Validate with recombinant protein standards: Include recombinant SLC25A34 as a positive control to establish a standard curve for quantification.

How does the mitochondrial localization of SLC25A34 impact experimental design and antibody selection?

The mitochondrial inner membrane localization of SLC25A34 significantly impacts experimental design and antibody selection:

• Sample preparation considerations:

  • For Western blot, consider mitochondrial isolation or enrichment protocols to increase sensitivity

  • For immunofluorescence/immunocytochemistry, ensure adequate permeabilization to allow antibody access to mitochondrial membranes

• Antibody epitope selection:

  • Antibodies targeting loops exposed to the intermembrane space or matrix may have different accessibility

  • Consider the topology of SLC25A34 (with its typical six transmembrane domains as a mitochondrial carrier family member)

• Co-localization studies:

  • Include established mitochondrial markers in immunofluorescence studies (MitoTracker dyes, TOMM20, COX IV)

  • Consider z-stack imaging to fully capture the three-dimensional mitochondrial network

• Functional studies:

  • Design experiments that assess mitochondrial function when modulating SLC25A34 expression

  • Consider measuring parameters like membrane potential, respiration, or metabolite transport

• Fixation methods:

  • Select fixation methods that preserve mitochondrial structure (methanol fixation at -20°C often works well)

  • Avoid over-fixation that might mask epitopes

• Controls for specificity:

  • Include non-mitochondrial markers to confirm specific mitochondrial localization

  • Use subcellular fractionation to biochemically validate mitochondrial localization

When selecting antibodies, prioritize those that have been validated specifically for detecting mitochondrial localization through immunofluorescence or fractionation studies.

What are the common troubleshooting issues with SLC25A34 antibodies in Western blot and how can they be resolved?

Common troubleshooting issues with SLC25A34 antibodies in Western blot and their solutions include:

• No signal or weak signal:

  • Increase antibody concentration (try 1:500 instead of 1:1000)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Increase protein loading (50-100 μg per lane)

  • Use enhanced chemiluminescence (ECL) substrate with higher sensitivity

  • Consider mitochondrial enrichment to concentrate the target protein

  • Ensure transfer efficiency, especially for membrane proteins

• Multiple bands or non-specific bands:

  • Increase blocking stringency (5% BSA instead of milk for phospho-specific antibodies)

  • Optimize antibody dilution to reduce non-specific binding

  • Use freshly prepared samples with complete protease inhibitor cocktail

  • Increase washing duration and number of washes

  • Try a gradient gel to better resolve proteins of similar molecular weight

  • Consider that multiple bands might represent post-translational modifications or splice variants

• Unexpected molecular weight:

  • The calculated molecular weight of SLC25A34 is 32.2 kDa

  • Post-translational modifications might alter apparent molecular weight

  • Membrane proteins may migrate aberrantly on SDS-PAGE

• High background:

  • Reduce antibody concentration

  • Increase washing time and number of washes

  • Use fresh blocking reagents

  • Ensure clean transfer apparatus and pure reagents

  • Try alternative blocking agents (BSA, casein, commercial blocking buffers)

• Optimization table for different lysis buffers:

How can researchers optimize ELISA protocols for SLC25A34 detection?

Optimizing ELISA protocols for SLC25A34 detection requires careful consideration of several parameters:

• Antibody selection and dilution:

  • Choose antibodies specifically validated for ELISA applications

  • Determine optimal antibody concentration through titration (typically between 1:20,000-1:40,000 for SLC25A34 detection)

  • For sandwich ELISA, ensure capture and detection antibodies recognize different epitopes

• Sample preparation:

  • For cell/tissue lysates, optimize extraction buffer composition to efficiently solubilize membrane proteins

  • Determine appropriate sample dilution through preliminary experiments

  • Consider mitochondrial enrichment for increased sensitivity

• Plate preparation and blocking:

  • For direct or indirect ELISA, optimize coating buffer (carbonate/bicarbonate buffer, pH 9.6)

  • Determine optimal antigen concentration for coating

  • Test different blocking agents (BSA, non-fat milk, commercial blockers) at various concentrations (1-5%)

• Assay development and optimization:

  • Test various incubation times and temperatures for each step

  • Optimize washing procedures (buffer composition, number of washes)

  • Compare different detection systems (colorimetric, chemiluminescent, fluorescent)

• Standard curve preparation:

  • Use recombinant SLC25A34 protein for standard curve generation

  • Ensure standards and samples are diluted in identical buffer conditions

  • Include a wide range of standard concentrations for accurate quantification

• Quality control:

  • Include positive and negative controls in each assay

  • Determine assay specificity through competitive inhibition with the immunizing peptide

  • Calculate intra- and inter-assay coefficient of variation

• Optimization protocol workflow:

What controls should be included when using SLC25A34 antibodies for immunofluorescence studies?

For rigorous immunofluorescence studies with SLC25A34 antibodies, researchers should include comprehensive controls:

• Essential negative controls:

  • Primary antibody omission: Apply only secondary antibody to detect non-specific binding

  • Isotype control: Use non-specific IgG from the same species as the primary antibody

  • Blocking peptide competition: Pre-incubate antibody with immunizing peptide

  • Biological negative control: Use cells/tissues with confirmed low/no expression of SLC25A34

• Positive controls:

  • Cells/tissues with confirmed high expression of SLC25A34

  • Cells transfected with SLC25A34 expression plasmid

  • Recombinant SLC25A34 protein spotted on slides (for antibody functionality testing)

• Subcellular localization controls:

  • Co-staining with established mitochondrial markers (MitoTracker, TOMM20, COX IV)

  • Counter-staining with markers for other organelles to confirm specificity

  • Z-stack imaging to confirm three-dimensional co-localization

• Expression modulation controls:

  • SLC25A34 knockdown/knockout cells to demonstrate reduced/absent signal

  • SLC25A34 overexpression to demonstrate increased signal

  • Treatment controls that may alter expression or localization

• Technical controls:

  • Autofluorescence control: Unstained sample to detect inherent fluorescence

  • Single-color controls for multi-color experiments to establish bleed-through parameters

  • Secondary antibody cross-reactivity control when performing multi-labeling

• Image acquisition controls:

  • Consistent exposure settings across samples

  • Multiple fields of view per condition

  • Blinded analysis when possible

When examining mitochondrial proteins like SLC25A34, it's particularly important to use high-resolution imaging techniques (confocal or super-resolution microscopy) to accurately visualize mitochondrial structures and confirm co-localization with known mitochondrial markers.

What methodological approaches are recommended for investigating SLC25A34 function in mitochondrial metabolism?

To investigate SLC25A34 function in mitochondrial metabolism, researchers should consider multiple complementary methodological approaches:

• Expression modulation strategies:

  • CRISPR/Cas9 gene editing to create knockout cell lines

  • siRNA or shRNA for transient or stable knockdown

  • Overexpression systems using tagged constructs (GFP, FLAG, HA)

  • Inducible expression systems to control timing of expression changes

• Mitochondrial function assays:

  • Oxygen consumption rate (OCR) measurement using Seahorse XF analyzer

  • Mitochondrial membrane potential assessment using fluorescent dyes (TMRM, JC-1)

  • ATP production assays

  • Reactive oxygen species (ROS) measurement

• Metabolite transport studies:

  • Radioisotope-labeled substrate uptake in isolated mitochondria

  • Liposome reconstitution with purified protein for transport assays

  • Metabolomics analysis of cells with modulated SLC25A34 expression

  • Substrate competition assays to identify transported molecules

• Protein interaction studies:

  • Co-immunoprecipitation to identify binding partners

  • Proximity labeling techniques (BioID, APEX)

  • Yeast two-hybrid screening

  • Blue native PAGE to examine complex formation

• Structural analysis:

  • Homology modeling based on other SLC25 family members

  • Site-directed mutagenesis of conserved residues

  • Cryo-EM or X-ray crystallography (challenging for membrane proteins)

• In vivo models:

  • Generation of knockout mouse models

  • Tissue-specific conditional knockout systems

  • Metabolic challenge studies in model organisms

  • Phenotypic characterization across different physiological states

• Experimental design recommendations:

How might advances in antibody technology improve future research on SLC25A34 and other mitochondrial proteins?

Advances in antibody technology are poised to significantly enhance SLC25A34 research and studies of other mitochondrial proteins:

• Recombinant antibody development:

  • Single-chain variable fragments (scFvs) and nanobodies with smaller size for better penetration into mitochondrial compartments

  • Fully human recombinant antibodies to reduce background in human samples

  • Engineered antibodies with increased affinity and specificity through directed evolution

• Multi-epitope targeting:

  • Development of antibody panels targeting different epitopes of SLC25A34

  • Validation through multiple independent antibodies to increase confidence in results

  • Epitope mapping to select antibodies targeting functionally relevant protein domains

• Advanced imaging applications:

  • Super-resolution microscopy-compatible antibodies with bright, photostable fluorophores

  • Antibodies optimized for expansion microscopy to visualize mitochondrial ultrastructure

  • Live-cell compatible antibody fragments for dynamic studies of protein localization

• Quantitative proteomics integration:

  • Antibodies validated for immunoprecipitation-mass spectrometry (IP-MS)

  • Standardized antibodies for absolute quantification of SLC25A34

  • Multiplexed antibody panels for simultaneous detection of multiple mitochondrial proteins

• Functional antibodies:

  • Development of function-blocking antibodies to inhibit transport activity

  • Conformation-specific antibodies that recognize active vs. inactive states

  • Antibodies that can distinguish post-translationally modified forms

• In vivo applications:

  • Blood-brain barrier penetrating antibodies for CNS mitochondrial research

  • Antibodies optimized for in vivo imaging of mitochondrial proteins

  • Tissue-clearing compatible antibodies for whole-tissue mitochondrial visualization

• Clinical translation potential:

  • Development of diagnostic antibodies if SLC25A34 is found to be altered in disease states

  • Therapeutic antibody conjugates targeting dysfunctional mitochondria

  • Companion diagnostic antibodies for mitochondrial-targeted therapeutics

• Emerging antibody technologies:

These advances will facilitate more precise characterization of SLC25A34's role in mitochondrial function and potentially uncover its involvement in both physiological processes and pathological conditions.